Investment Summary

NMT Capital Invests In Kiyatec

On May 23, 2012, private equity firm NMT Capital invested in life science company Kiyatec

Investment Highlights
  • This is NMT Capital’s 3rd transaction in the Life Science sector.
  • This is NMT Capital’s 8th transaction in the United States.
  • This is NMT Capital’s 2nd transaction in South Carolina.

Investment Summary
Date 2012-05-23
Target Kiyatec
Sector Life Science
Investor(s) NMT Capital
Deal Type Venture

Target

Kiyatec

Greenville, South Carolina, United States
Kiyatec is commercializing novel 3D cell culture technology, developed at Clemson University, and is providing tools for researchers and clinicians with advanced in vitro models for improved understanding in cell and systems biology, drug development, and clinical diagnosis. Kiyatec was founded in 2005 and is based in Greenville, South Carolina.

Search 200,626 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

NMT Capital

Norwell, Massachusetts, United States
Category Private Equity Firm
Size Small
Type Sector Agnostic
DESCRIPTION

NMT Capital is a private equity firm focused on tech-oriented growth industries. Areas of interest include medical devices, diagnostics, biotechnology, specialty pharmaceutical, drug discovery tools, software, communications, information technology, and advanced materials. NMT Capital is based in Quincy, Massachusetts.

DEAL STATS #
Overall 11 of 11
Sector (Life Science) 3 of 3
Type (Venture) 10 of 10
State (South Carolina) 2 of 2
Country (United States) 8 of 8
Year (2012) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2012-03-12 iovera

Fremont, California, United States

MyoScience, Inc. is a medical device company committed to making its platform technology, the iovera° system, the standard of care for the treatment of peripheral nerves. MyoScience, Inc. was founded in 2005 and is based in Fremont, California.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2012-10-18 Presidio Pharmaceuticals

San Francisco, California, United States

Presidio Pharmaceuticals is a specialty pharmaceutical company focusing on in-licensing, developing, and commercializing novel and validated therapeutics for chronic viral infections, including HIV-1, HCV, and CMV. Presidio Pharmaceuticals was founded in 2006 and is based in San Francisco, California.

Sell $101M
Mergr

Product

Company

Legal